Towards elimination of measles and rubella in Italy: Progress and challenges.
Adolescent
Adult
Child
Child, Preschool
Disease Eradication
/ methods
Disease Outbreaks
/ prevention & control
Female
Humans
Incidence
Infant
Infant, Newborn
Italy
/ epidemiology
Male
Measles
/ epidemiology
Measles Vaccine
/ therapeutic use
Middle Aged
Population Surveillance
Pregnancy
Quality Indicators, Health Care
Rubella
/ epidemiology
Vaccination
/ methods
Vaccination Coverage
/ methods
World Health Organization
Young Adult
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
27
09
2019
accepted:
27
11
2019
entrez:
17
12
2019
pubmed:
17
12
2019
medline:
17
4
2020
Statut:
epublish
Résumé
In the WHO European Region, endemic transmission of measles and rubella had been interrupted by 37 and 42 of the 53 member states (MSs), respectively, by 2018. Sixteen MSs are still endemic for measles, 11 for rubella and nine for both diseases, the latter including Italy. Elimination is documented by each country's National Verification Committee (NVC) through an annual status update (ASU). By analysing data used to produce the ASUs, we aimed to describe the advances made by Italy towards elimination of measles and rubella. Moreover, we propose a set of major interventions that could facilitate the elimination process. A total of 28 indicators were identified within the six core sections of the ASU form and these were evaluated for the period 2013-2018. These indicators relate to the incidence of measles/rubella; epidemiological investigation of cases; investigation of outbreaks; performance of the surveillance system; population immunity levels; and implementation of supplemental immunization activities (SIAs). From 2013 to 2018, epidemiological and laboratory analyses of measles cases in Italy improved substantially, allowing timely investigation in 2017 and 2018 of most outbreak and sporadic cases and identification of the majority of genotypic variants. Moreover, since 2017, vaccination coverage has increased significantly. Despite these improvements, several areas of concern emerged, prompting the following recommendations: i) improve outbreak monitoring; ii) strengthen the MoRoNet network; iii) increase the number of SIAs; iv) reinforce vaccination services; v) maintain regional monitoring; vi) design effective communication strategies; vii) foster the role of general practitioners and family paediatricians. The review of national ASUs is a crucial step to provide the NVC with useful insights into the elimination process and to guide the development of targeted interventions. Against this background, the seven recommendations proposed by the NVC have been shared with the Italian Ministry of Health and the Technical Advisory Group on measles and rubella elimination and have been incorporated into the new Italian Elimination Plan 2019-2023 as a technical aid to facilitate the achievement of disease elimination goals.
Identifiants
pubmed: 31841530
doi: 10.1371/journal.pone.0226513
pii: PONE-D-19-27165
pmc: PMC6913993
doi:
Substances chimiques
Measles Vaccine
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0226513Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Health Policy. 2015 Jun;119(6):760-9
pubmed: 25887486
Int J Equity Health. 2016 Feb 19;15:28
pubmed: 26892002
PLoS One. 2018 Oct 24;13(10):e0205147
pubmed: 30356247
Eur J Public Health. 2015 Dec;25(6):1117-9
pubmed: 25958239
Vaccine. 2014 Aug 27;32(38):4860-5
pubmed: 24262311
Med Mal Infect. 2016 May;46(3):117-22
pubmed: 26987960
Public Health. 2016 Jan;130:51-8
pubmed: 26427315
Euro Surveill. 2018 Apr;23(17):
pubmed: 29717694
Ig Sanita Pubbl. 2017 Sep-Oct;73(5):429-442
pubmed: 29433130
Euro Surveill. 2017 Sep 14;22(37):null
pubmed: 28933342
Euro Surveill. 2013 May 16;18(20):null
pubmed: 23725868
Soc Sci Med. 2014 Jul;112:1-11
pubmed: 24788111
Vaccine. 2018 May 31;36(23):3368-3374
pubmed: 29729995
MMWR Morb Mortal Wkly Rep. 2017 Nov 17;66(45):1256-1260
pubmed: 29145358
Vaccine. 2018 Feb 1;36(6):779-787
pubmed: 29325822
Hum Vaccin Immunother. 2018 Jul 3;14(7):1558-1565
pubmed: 29641945
Emerg Infect Dis. 2015 Aug;21(8):1444-6
pubmed: 26196266
Vaccine. 2012 May 28;30(25):3778-89
pubmed: 22172504
Vaccine. 2019 Mar 28;37(14):1954-1963
pubmed: 30827733
Ann Ig. 2012 Sep-Oct;24(5):397-405
pubmed: 23193896
Vaccine. 2019 Feb 8;37(7):984-990
pubmed: 30655175
Ann Ig. 2017 Jan-Feb;29(1):1-26
pubmed: 28067934
Vaccine. 2017 Aug 16;35(35 Pt B):4494-4498
pubmed: 28736200
Ital J Pediatr. 2018 Jun 14;44(1):67
pubmed: 29898770
Int J Infect Dis. 2019 Feb;79:199-201
pubmed: 30445191